Literature DB >> 20696169

Pharmacokinetic immunoassay methods in the presence of soluble target.

Thorsten Verch1, Shannon Chilewski, Silikhone Bouaraphan, Helen Yarovoi, Kuo-Chang Yin, Dave Chen, Michael W Washabaugh.   

Abstract

Soluble targets represent a special challenge when employing ligand binding assays to support pharmacokinetic analysis of monoclonal therapeutics. Target-engaged antibody is not available for binding in immunoassays employing anti-idiotype-specific antibodies or target for capture. We investigated several formats of total antibody assays that show reduced interference of soluble targets: direct target capture, indirect target capture and acid dissociation. While indirect target capture worked well for a regular affinity antibody against DKK1, a high affinity antibody against PCSK9 required an additional acid dissociation step. The choice of a suitable format was antibody and target dependent. Our results offer several choices to approach immunoassay development for soluble targets.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696169     DOI: 10.1016/j.jim.2010.07.014

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

Review 1.  Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?

Authors:  Andrew P Mayer; Charles S Hottenstein
Journal:  AAPS J       Date:  2015-12-15       Impact factor: 4.009

2.  Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.

Authors:  Xiangdan Wang; Valerie Quarmby; Carl Ng; Anan Chuntharapai; Theresa Shek; Charles Eigenbrot; Robert F Kelley; Steven Shia; Krista McCutcheon; John Lowe; Cecilia Leddy; Kyle Coachman; Gary Cain; Felix Chu; Isidro Hotzel; Mauricio Maia; Eric Wakshull; Jihong Yang
Journal:  MAbs       Date:  2013-04-29       Impact factor: 5.857

3.  Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.

Authors:  Stefan Harth; Christian Frisch
Journal:  Methods Mol Biol       Date:  2021

4.  Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

Authors:  Stefan Harth; Andre Ten Haaf; Christian Loew; Christian Frisch; Achim Knappik
Journal:  MAbs       Date:  2018-12-05       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.